PSNL - Personalis Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD, November 7-10, including poster presentations on November 8th and 9th.
The company will showcase ImmunoID NeXT™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Following is a list of abstracts that will be presented at the meeting.
Scientific Poster Presentations
Poster Number & Category |
Title & Presenter |
Day & Time |
Location |
P77 Biomarkers, Immune Monitoring, and Novel Technologies |
Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms Presenter: Charles Abbott, Ph.D. |
November 8: |
Poster Hall: Prince George AB |
P72 Biomarkers, Immune Monitoring, and Novel Technologies |
Comprehensive and accurate prediction of presented neoantigens using ImmunoID NeXT and advanced machine learning algorithms Presenters: Dattatreya Mellacheruvu, Ph.D. and Rachel Pyke, Ph.D. |
November 9: |
Poster Hall: Prince George AB |
P96 Biomarkers, Immune Monitoring, and Novel Technologies |
T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome Presenter: Eric Levy, Ph.D. |
November 9: |
Poster Hall: Prince George AB |
Personalis will also be exhibiting during the conference (Booth # 431). Representatives will be available to answer questions about the company’s cancer immunogenomics services.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005817/en/
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678
Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300